Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Faruqi & F ...

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Semler Scientific did not disclose a material investigation by the United States Department of Justice (the "DOJ") into violations of the False Claims Act, while discussing possible violations of the False Claims (and aggressive DOJ enforcement thereof) in hypothetical terms; and (2) as a result, defendants public stat ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of violations of federal securities laws, particularly concerning misleading statements about its product SLK compared to BIMZELX [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against MoonLake [4]. - Investors who suffered losses in MoonLake between March 10, 2024, and September 29, 2025, are encouraged to contact the firm to discuss their legal rights [1][9]. - The complaint alleges that MoonLake and its executives made false statements regarding the efficacy and clinical benefits of SLK compared to traditional monoclonal antibodies [6]. Group 2: Stock Performance and Market Reaction - Following the announcement of disappointing results from the Phase 3 VELA program on September 28, 2025, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [7]. - The results indicated that SLK did not demonstrate competitive efficacy relative to BIMZELX, leading to significant investor losses [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. - The firm has offices in New York, Pennsylvania, California, and Georgia, indicating a broad operational footprint [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed challenges affecting the company's performance [4][6]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $75,000 in RxSight between May 7, 2024, and July 8, 2025, to discuss their legal options [1]. - There is a deadline of September 22, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against RxSight [4]. - The complaint alleges that RxSight and its executives made false statements regarding the company's sales and utilization, overstated product demand, and failed to meet previously issued financial guidance for fiscal year 2025 [6]. Group 2: Financial Performance and Market Reaction - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in LDD sales, LAL utilization, and overall revenue, leading to a lowered full-year guidance by approximately $42.5 million at the midpoint [7]. - Following the announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, with unusually heavy trading volume [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of securities law violations related to misleading statements and the promotion of unsafe products [3][5]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Hims, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [3][7]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which jeopardized patient safety and risked the termination of its collaboration with Novo Nordisk [5][6]. Group 2: Impact on Stock Price - Following Novo Nordisk's announcement of ending its partnership with Hims due to legal violations, Hims' stock price dropped by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025 [6]. Group 3: Call for Information - Faruqi & Faruqi encourages individuals with information regarding Hims' conduct, including whistleblowers and former employees, to come forward [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Perpetua Resources Corp due to allegations of violations of federal securities laws related to misleading statements about the Stibnite Gold Project, which led to significant financial losses for investors [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Perpetua between April 17, 2024, and February 13, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Perpetua, with a deadline of May 20, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Perpetua and its executives made false or misleading statements regarding the true costs and financial projections of the Stibnite Gold Project, which inflated the stock price [4]. Group 2: Financial Impact and Stock Performance - Following the release of an updated cash flow model for the Stibnite Gold Project on February 13, 2025, Perpetua's stock price fell over 22% on February 14, 2025 [5][6]. - The updated financial model indicated an increase in initial and total capital expenditures, which contrasted with previous estimates, although it also noted improvements in key economic metrics such as Annual Average EBITDA and Free Cash Flow [5]. Group 3: Company Background and Contact Information - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Perpetua's conduct [8].